Following the Science
By following the science and leveraging our insights into the pathophysiology of acquired brain injury, we are advancing a pipeline of small molecule disease-modifying candidates targeting the underserved patient populations who have suffered an ischemic stroke or a traumatic brain injury (TBI) and continue to deal with the devastating effects and consequences of loss of function or cognitive deficits.
Recent advances in the management of stroke and traumatic brain injury and our ability to study and characterize these conditions have reopened doors to exploring previously untapped therapeutic approaches.
- Standardized clinical trial pathways and efficacy endpoints enable targeting of homogeneous subpopulations.
- Health care system infrastructure and technology advances (accreditation, triage, diagnostics, imaging, artificial intelligence, mobile stroke units, telemedicine) are enabling faster diagnosis and treatment within the window for effective use of tissue plasminogen activator (tPA).
- Removal of clots by mechanical thrombectomy (MT) – a procedure gaining traction since 2015 – restores perfusion effectively in some patients, enabling neuroactive drugs to reach compromised brain tissue.
While our initial focus is on ischemic stroke, we are also exploring therapies targeting traumatic brain injury, a condition that shares many of the common underlying features of stroke.
NTS is developing a growing pipeline of disease-modifying candidates that target the fundamental underlying pathophysiologic drivers and processes that lead to structural damage and functional deficits in stroke and TBI. These programs aim to address the immediate period following the stroke or TBI event as well as the management of the deficits that persist in the weeks to months following the event, as the patient returns to their pre-injury activities.
Our lead candidate, NTS-104, is a novel neuroactive small molecule that has demonstrated efficacy in preclinical models of acute ischemic stroke and TBI. NTS-104, a pro-drug, is soluble in plasma, where it is converted to NTS-105. NTS-105 has shown substantial brain penetrance and is able to achieve concentrations in the brain sufficient to modulate key target receptors protecting neurons from inflammation, ischemia, and hypoxia.
Since licensing the candidates from Emory University, we have made significant progress advancing the candidates forward toward the clinic and are currently exploring the effects of NTS-104 at various time points following stroke in pre-clinical models.